Companies › Oruka Therapeutics
2 active drug programs in 6 registered trials: 5 Phase 2, 1 Phase 1; Immunology, Other; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ORKA-001 | – | Phase 2 | Plaque Psoriasis | May 2027 |
| ORKA-002 | – | Phase 2 | Plaque Psoriasis; Hidradenitis Suppurativa (HS); Healthy Volunteers | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06944379 | ORKA-002 | Phase 1 | Healthy Volunteers | Other | Aug 2026 |
| NCT07090330 | ORKA-001 | Phase 2 | Plaque Psoriasis | Immunology | May 2027 |
| NCT07474792 | ORKA-002 | Phase 2 | Plaque Psoriasis | Immunology | Oct 2027 |
| NCT07783542 | ORKA-002 | Phase 2 | Hidradenitis Suppurativa (HS) | Immunology | Oct 2028 |
| NCT07290569 | ORKA-001 | Phase 2 | Plaque Psoriasis | Immunology | Dec 2028 |
| NCT07449702 | ORKA-001 | Phase 2 | Plaque Psoriasis | Immunology | May 2030 |
Cash and short-term investments of $920m on 2026-09-30; operating cash outflow about $136m a year; runway about 81 months at that burn, to Jul 2033; 5 of 5 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Palisade Bio Shattuck Labs Spyre Therapeutics Sagimet Biosciences Abivax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.